CORDIS · 603038 · FP7
CFMATTERS Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified.
Coordinator: UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE)
Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caused by a multitude of organisms that traditionally evolve various mechanisms of resistance. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudom…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 3.7 years from 2013-10-01 to 2017-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from IE
see all →- MSCA4Ukraine — MSCA4Ukraine101101923 · HORIZON · €35.0M
- WaterLANDS — Water-based solutions for carbon storage, people and wilderness101036484 · H2020 · €23.1M
- INFRACHIP — European Research Infrastructure on Semiconductor Chips101131822 · HORIZON · €14.5M
- PRIMES — PRIMES: Protein interaction machines in oncogenic EGF receptor signalling278568 · FP7 · €12.0M
- NAMDIATREAM — NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING246479 · FP7 · €12.0M
- REALLOCATE — Rethinking the dEsign of streets And pubLic spaces to Leverage the mOdal shift to Climate-friendly Active Transport Everywhere101103924 · HORIZON · €12.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-FP funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE).
- What is the project timeline?
- The project runs from 2013-10-01 to 2017-06-30 — approximately 3.7 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 603038.